Furthermore, miR-342 was competitively bound by SCARNA2, a non-coding RNA highly expressed in CRC tissues, thus leading to a secondary upregulation of both the epidermal growth factor receptor (EGFR) and BCL2 oncoproteins and to a sustained 5-FU resistance [17]. This evidence concerns the gene BCL2 and colorectal carcinoma.